You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

SARS-CoV-2 mRNA vaccine

Showing 1 - 25 of >10,000
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

SARS-CoV-2 Trial in Chengdu (SARS-CoV-2 mRNA vaccine (RBMRNA), CoronaVac®)

Active, not recruiting
  • SARS-CoV-2
  • SARS-CoV-2 mRNA vaccine (RBMRNA)
  • CoronaVac®
  • Chengdu, Sichuan, China
    Chengdu Xinhua Hospital affiliated to North Sichuan Medical Coll
Jun 12, 2023

SARS-CoV-2 Trial in Chengdu (RBMRNA-176, Placebo)

Active, not recruiting
  • SARS-CoV-2
  • RBMRNA-176
  • Placebo
  • Chengdu, Sichuan, China
    Chengdu Xinhua Hospital affiliated to North Sichuan Medical Coll
Jun 12, 2023

SARS-CoV-2 Trial (LVRNA009, 0.9%NaCl)

Not yet recruiting
  • SARS-CoV-2
  • LVRNA009
  • 0.9%NaCl
  • (no location specified)
Jan 11, 2023

SARS-CoV-2 Trial (SARS-CoV-2 mRNA Vaccine, Bivalent Low dose, SARS-CoV-2 mRNA Vaccine, Bivalent High dose, Placebo)

Recruiting
  • SARS-CoV-2
  • SARS-CoV-2 mRNA Vaccine, Bivalent Low dose
  • +2 more
  • Bengbu, Anhui, China
    First Affiliated Hospital Bengbu Medical College
Jan 3, 2023

SARS-CoV-2, Safety, Immunotoxicity Trial in Wuhan (one dose of the study SARS-CoV-2 mRNA Vaccine (SYS6006), Cellular Immunity,

Not yet recruiting
  • SARS-CoV-2
  • +2 more
  • one dose of the study SARS-CoV-2 mRNA Vaccine (SYS6006)
  • +3 more
  • Wuhan, Hubei, China
    Zhongnan Hospital of Wuhan University
Aug 9, 2022

COVID-19 Trial in Nanjing, Hangzhou (20 µg dose of SYS6006, 30 µg dose of SYS6006, Placebo)

Enrolling by invitation
  • SARS-CoV-2
  • 20 μg dose of SYS6006 ;30 μg dose of SYS6006
  • Placebo
  • Nanjing, Jiangsu, China
  • +1 more
Dec 20, 2022

COVID-19 Trial in Nanjing, Hangzhou (20 µg dose of SYS6006, 30 µg dose of SYS6006, Placebo)

Enrolling by invitation
  • SARS-CoV-2
  • 20 μg dose of SYS6006；30 μg dose of SYS6006
  • Placebo
  • Nanjing, Jiangsu, China
  • +1 more
Dec 20, 2022

SARS-CoV-2 Trial in Islamabad (LVRNA009, CoronaVac®)

Not yet recruiting
  • SARS-CoV-2
  • LVRNA009
  • CoronaVac®
  • Islamabad, Pakistan
    Clinical Trial Unit, National Institute of Health
Jun 22, 2022

COVID-19 Trial in Yuncheng, Hangzhou (Low-dose of LVRNA009, Middle-dose of LVRNA009, High-dose of LVRNA009)

Active, not recruiting
  • COVID-19
  • Low-dose of LVRNA009
  • +3 more
  • Changsha, Hunan, China
  • +2 more
Dec 1, 2022

SARS-CoV-2 Infection Trial in Shijia Zhuang (SYS6006)

Recruiting
  • SARS-CoV-2 Infection
  • SYS6006
  • Shijia Zhuang, Hebei, China
    Hebei Provincial Center For Disease Control and Prevention
Jul 4, 2022

SARS-CoV-2 Trial in Changsha, Xiangtan (SARS-CoV-2 (LVRNA009) 50µg group, SARS-CoV-2 (LVRNA009) 100µg group, Placebo)

Active, not recruiting
  • SARS-CoV-2
  • SARS-CoV-2 (LVRNA009) 50μg group
  • +2 more
  • Changsha, Hunan, China
  • +1 more
Jul 19, 2022

SARS-CoV-2 Trial in Jiangsu (BNT162b2, Placebo)

Completed
  • SARS-CoV-2
  • BNT162b2
  • Placebo
  • Jiangsu, China
    Jiangsu Provincial Center for Disease Control and Prevention
May 9, 2022

Post-marketing Safety of Elasomeran/Davesomeran and Andusomeran

Recruiting
  • SARS-CoV-2
  • SPIKEVAX
  • New York, New York
    Aetion, Inc
Nov 8, 2023

SARS-CoV-2 Trial in Nanjing (SARS-CoV-2 Bivalent mRNA Vaccine, Recombinant SARS-CoV-2 vaccine, Saline)

Not yet recruiting
  • SARS-CoV-2
  • SARS-CoV-2 Bivalent mRNA Vaccine
  • +2 more
  • Nanjing, Jiangsu, China
    Jiangsu Provincial Center for Disease Control and Prevention
Jul 7, 2023

SARS-CoV-2 Trial in Nanjing (SARS-CoV-2 Bivalent mRNA Vaccine, Saline)

Not yet recruiting
  • SARS-CoV-2
  • SARS-CoV-2 Bivalent mRNA Vaccine
  • Saline
  • Nanjing, Jiangsu, China
    Jiangsu Provincial Center for Disease Control and Prevention
Jul 7, 2023

Chronic Lymphocytic Leukemia, COVID-19 Infection Trial in Duarte (Biospecimen Collection, mRNA COVID-19 Vaccine, Synthetic

Not yet recruiting
  • Chronic Lymphocytic Leukemia
  • COVID-19 Infection
  • Biospecimen Collection
  • +2 more
  • Duarte, California
    City of Hope Medical Center
Jan 3, 2023

IgG Antibodies After SARS-CoV-2 mRNA Vaccine in Kidney

Active, not recruiting
  • Kidney Transplantation
  • anti-spike SARS-CoV-2 IgG
  • Prague, Czechia
    Institute for Clinical and Experimental Medicine
Dec 16, 2021

COVID-19 Trial in Worldwide (SARS-CoV-2 mRNA vaccine formulation 1, SARS-CoV-2 mRNA vaccine formulation 2, SARS-CoV-2 mRNA

Terminated
  • COVID-19
  • SARS-CoV-2 mRNA vaccine formulation 1
  • +3 more
  • Rolling Hills Estates, California
  • +20 more
Aug 22, 2022

SARS-CoV-2 Trial (SARS-CoV-2 variant mRNA vaccine low dose, SARS-CoV-2 variant mRNA vaccine high dose)

Not yet recruiting
  • SARS-CoV-2
  • SARS-CoV-2 variant mRNA vaccine low dose
  • SARS-CoV-2 variant mRNA vaccine high dose
  • (no location specified)
Oct 30, 2022

SARS-CoV-2 Trial in Islamabad (SARS-CoV-2 Bivalent mRNA vaccine (LVRNA021), 0.9% sodium chloride solution)

Recruiting
  • SARS-CoV-2
  • SARS-CoV-2 Bivalent mRNA vaccine (LVRNA021)
  • 0.9% sodium chloride solution
  • Islamabad, Pakistan
    Sindh Infectious Diseases Hospital & Research Center Dow Univers
Apr 16, 2023

Coronavirus, Covid19, SARS-CoV-2 Trial in Brussels, Liège (CVnCoV Vaccine)

Terminated
Has Results
  • Coronavirus
  • +3 more
  • CVnCoV Vaccine
  • Brussels, Belgium
  • +3 more
Apr 20, 2022

Immunogenicity, Safety Trial (Phase II:SWIM816;SARS-Cov-2;, Phase II:SW-BIC-213;SARS-Cov-2;, PhaseIII:SWIM816;SARS-Cov-2;)

Not yet recruiting
  • Immunogenicity
  • Safety
  • Phase II:SWIM816;SARS-Cov-2;
  • +3 more
  • (no location specified)
Jun 18, 2023

SARS-CoV-2 Trial (SARS-CoV-2 Variant (Omicron BA.5) mRNA Vaccine low dose, SARS-CoV-2 Variant (Omicron BA.5) mRNA Vaccine high

Not yet recruiting
  • SARS-CoV-2
  • SARS-CoV-2 Variant (Omicron BA.5) mRNA Vaccine low dose
  • +2 more
  • (no location specified)
Dec 1, 2022

SARS-CoV-2 Trial in Bengbu (SARS-CoV-2 Variant (Omicron BA.5) mRNA vaccine Low dose, SARS-CoV-2 Variant (Omicron BA.5) mRNA

Active, not recruiting
  • SARS-CoV-2
  • SARS-CoV-2 Variant (Omicron BA.5) mRNA vaccine Low dose
  • +2 more
  • Bengbu, Anhui, China
    First Affiliated Hospital Bengbu Medical College
Jan 3, 2023

SARS-CoV-2 Trial in Bengbu (SARS-CoV-2 Variant (Omicron BA.5) mRNA vaccine, Saline solution)

Recruiting
  • SARS-CoV-2
  • SARS-CoV-2 Variant (Omicron BA.5) mRNA vaccine
  • Saline solution
  • Bengbu, Anhui, China
    First Affiliated Hospital Bengbu Medical College
Feb 26, 2023